Target Information

Target General Information

Top

Target ID

T60810 (Former ID: TTDI01189)

Target Name

Cell mediated immunity response (CMIR)

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 6 Target-related Diseases

Acute viral hepatitis [ICD-11: 1E50]

Hepatitis virus infection [ICD-11: 1E50-1E51]

Human immunodeficiency virus disease [ICD-11: 1C60-1C62]

Influenza [ICD-11: 1E30-1E32]

Postoperative inflammation [ICD-11: 1A00-CA43]

Whooping cough [ICD-11: 1C12]

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 11 Approved Drugs

Arepanrix

Drug Info

Approved

Influenza virus infection

[2], [3]

Celtura

Drug Info

Approved

Influenza virus infection

[2]

Fendrix

Drug Info

Approved

Hepatitis B virus infection

[2]

Focetria A(H1N1)

Drug Info

Approved

Influenza virus infection

[2]

GSK2592984A

Drug Info

Approved

Influenza virus infection

[2], [4]

H1N1 pandemic influenza A vaccine

Drug Info

Approved

Influenza virus infection

[2], [5]

H5N1 influenza vaccine

Drug Info

Approved

Human immunodeficiency virus infection

[6]

HEV-239

Drug Info

Approved

Hepatitis E virus infection

[7], [8]

Live attenuated influenza vaccine

Drug Info

Approved

Influenza virus infection

[2]

Polyoxidonium

Drug Info

Approved

Infectious disease

[2]

Quattvaxem

Drug Info

Approved

Bordetella pertussis infection

[2]

Clinical Trial Drug(s)

[+] 12 Clinical Trial Drugs

Grippol Plus

Drug Info

Phase 3

Influenza virus infection

[9]

Grippol TC

Drug Info

Phase 3

Influenza virus infection

[9]

H1N1 influenza vaccine

Drug Info

Phase 3

Influenza virus infection

[10]

H5N1 influenza vaccine

Drug Info

Phase 3

Influenza virus infection

[11]

HB-AS02V

Drug Info

Phase 3

Hepatitis B virus infection

[12]

H5N1 influenza vaccine

Drug Info

Phase 2

Influenza virus infection

[13]

HBV vaccine

Drug Info

Phase 2

Hepatitis B virus infection

[14]

LEISH-F1

Drug Info

Phase 2

Leishmania infection

[15]

Aflunov

Drug Info

Phase 1/2

Influenza A virus H5N1 infection

[16]

AFO-18

Drug Info

Phase 1

Human immunodeficiency virus-1 infection

[17]

CAF-01

Drug Info

Phase 1

Vaccination

[18]

GMZ-2

Drug Info

Phase 1

Malaria

[19]

Discontinued Drug(s)

[+] 1 Discontinued Drugs

H1N1 influenza vaccine

Drug Info

Discontinued in Phase 3

Influenza virus infection

[20]

Mode of Action

[+] 1 Modes of Action

Modulator

[+] 2 Modulator drugs

Polyoxidonium

Drug Info

[2], [28]

CAF-01

Drug Info

[37]

References

Top

REF 1

Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc. 2008 Jan;83(1):77-84.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 3

ClinicalTrials.gov (NCT01114620) Study of GSK Biologicals' Influenza Vaccine Arepanrix in Japanese Adults 65 Years of Age or Older. U.S. National Institutes of Health.

REF 4

ClinicalTrials.gov (NCT01196026) Immunogenicity and Safety Study of Fluarix Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix . U.S. National Institutes of Health.

REF 5

ClinicalTrials.gov (NCT01008137) Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults. U.S. National Institutes of Health.

REF 6

Clinical pipeline report, company report or official report of GlaxoSmithKline.

REF 7

ClinicalTrials.gov (NCT02189603) Phase Clinical Trial of Recombinant Hepatitis E Vaccine ecolin . U.S. National Institutes of Health.

REF 8

The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14.

REF 9

Clinical pipeline report, company report or official report of Solvay SA.

REF 10

Clinical pipeline report, company report or official report of Sanofi Pasteur.

REF 11

Clinical pipeline report, company report or official report of Daiichi Sankyo.

REF 12

ClinicalTrials.gov (NCT00291980) A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.. U.S. National Institutes of Health.

REF 13

ClinicalTrials.gov (NCT00430521) Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A). U.S. National Institutes of Health.

REF 14

ClinicalTrials.gov (NCT01777295) Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System. U.S. National Institutes of Health.

REF 15

An overview on Leishmania vaccines: A narrative review article. Vet Res Forum. 2015 Winter;6(1):1-7.

REF 16

ClinicalTrials.gov (NCT00814385) Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04. U.S. National Institutes of Health.

REF 17

ClinicalTrials.gov (NCT01009762) Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection. U.S. National Institutes of Health.

REF 18

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014 Dec 12;32(52):7098-107.

REF 19

ClinicalTrials.gov (NCT00424944) Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine. U.S. National Institutes of Health.

REF 20

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039884)

REF 21

Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57.

REF 22

A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43.

REF 23

Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7.

REF 24

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ. 2013 Feb 4;346:f393.

REF 25

Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80.

REF 26

How Influenza (Flu) Vaccines Are Made. FLU.gov. 2014.

REF 27

Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6.

REF 28

Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes. Russ J Immunol. 2003 Apr;8(1):53-60.

REF 29

Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005 Feb 25;23(14):1715-9.

REF 30

Clinical pipeline report, company report or official report of Petrovax.

REF 31

Clinical pipeline report, company report or official report of Sanofi Pasteur.

REF 32

Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza and Other Respiratory Viruses Volume 2, Issue 6, pages 261-266, November 2008.

REF 33

Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010 Jul;6(7):578-84.

REF 34

ClinicalTrials.gov (NCT00508833) Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615). U.S. National Institutes of Health.

REF 35

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011 Apr 27;29(19):3531-7.

REF 36

Aflunov( ): a prepandemic influenza vaccine. Expert Rev Vaccines. 2012 Feb;11(2):145-57.

REF 37

Mechanisms of Action of Adjuvants. Front Immunol. 2013; 4: 114.

REF 38

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J. 2011; 10: 359.

REF 39

Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol. 2012 Dec 3;13:165.

REF 40

Calcium Phosphate Nanoparticle Adjuvant. Clin Diagn Lab Immunol. 2000 November; 7(6): 899-903.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN